Daiichi Sankyo H1N1, Avian Flu Combo Drug Moves Into Phase III Trials
This article was originally published in PharmAsia News
Daiichi Sankyo says it has moved into Phase III trials with the first flu drug, CS-8958 (laninamivir), to treat both H1N1 and the avian virus
You may also be interested in...
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.
US regulators refused to accept the file for one of Y-mAbs's neuroblasoma drugs – omburtamab – in October but have given the green light to a second one, naxitamab.
Fueled by a pipeline of more than 15 biosimilar candidates, Sandoz is aiming to treble the size of its $2bn global biosimilars business by 2030, targeting the US, Europe and Japan. Management spoke at length about the firm’s achievements and prospects during a meeting of parent Novartis’ management.